Ask Yourself These 6 Questions Before You Get Medicare

Medicare enrollment timing and coverage choices carry material long-term cost implications: missing the Initial Enrollment Period can incur a 10% premium increase for every 12-month delay and permanent penalties, while beneficiaries remain liable for deductibles, coinsurance and non-covered services such as dental, vision and hearing. Financial planning should include assessing Parts A/B/C/D, IRMAA exposure, the tradeoff between Medigap and Medicare Advantage (including limited guaranteed-issue windows), and a review of 2025 out-of-pocket spending to model multi-decade healthcare costs (characterized in the article as roughly a $200,000 decision).

Analysis

Market structure: Expect concentrated revenue gains for large Medicare Advantage and Part D incumbents (UNH, HUM, ELV, CVS) driven by higher stickiness in renewals and up‑sell of supplements; regional hospitals and legacy Medigap specialists will face margin pressure from narrower MA networks and negotiated rates. Pricing power shifts to vertically integrated payors and PBMs; expect 2–4% EPS tailwinds for top MA players over 12–18 months if membership growth stays stable, while provider EBITDA margins compress by 100–300bp in pressured markets.

Risk assessment: Primary tail risks are regulatory reimbursement cuts (CMS rule changes) and adverse-selection shocks if guaranteed-issue windows widen; a 100–200bp cut in MA benchmarks would be high‑impact. Near term (next 90 days) enrollment AEP flows drive sentiment and IV spikes; medium term (6–12 months) claims trend and CMS final rules set profitability; long term (3–5 years) behavioral interactions with IRMAA/RMDs can create retiree asset-sales into markets.

Trade implications: Favor overweight insurance/ PBM exposure and underweight hospital/ elective-care names. Use directional equity and credit for payors, tactical option plays around AEP to monetize volatility, and short regional hospital operators to express compressed provider pricing. Entry window: put core positions in place in Sept–early Oct, trim or reassess post‑AEP (Jan–Feb) when enrollee data is public.

Contrarian angles: Market may be underestimating behavioral planning (IRMAA-driven withdrawal timing) that benefits annuity/wealth managers and creates predictable tax‑lot liquidations; conversely, consensus longs in insurers are vulnerable to a regulatory shock that is under-hedged. Historical Part D rollout shows fast revenue reallocation but also transient margin hits — plan for a two‑stage move (initial re-rating, then normalization).

Key Decisions for Investors

• Initiate 2–3% long positions in UnitedHealth (UNH) and Humana (HUM) split equally in Sept ahead of Annual Election Period; complement with 12‑month LEAP calls 10% OTM sized at 0.5% notional each to lever upside while capping cost.
• Pair trade: go long Elevance Health (ELV) 2% and short HCA Healthcare (HCA) 2% to express payor pricing power vs provider margin pressure; target profit at 20–30% move or time stop at 6 months.
• Buy a 6–9 month call spread on CVS (bullish Part D capture) costing <0.7% portfolio exposure (buy 5%–10% OTM, sell 20% OTM) entered in Sept and exited after Feb enrollment stats.
• Establish a protective hedge: purchase 12‑month put spreads on a basket of top MA names (UNH/HUM/ELV) sized 0.5–1% portfolio to limit downside if CMS final rule cuts MA rates >100bps (monitor CMS publications in next 60–90 days).